Clinical relevance of JAK2 (V617F) mutant allele burden

被引：60
|
作者：
Passamonti, Francesco [1 ]
Rumi, Elisa [1 ]
机构：
[1] Univ Pavia, Fdn IRCCS Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 01期
关键词：
POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; WILD-TYPE; MUTATION; JAK2V617F; MYELOFIBROSIS; JAK2(V617F); RISK; PROGRESSION; GRANULOCYTE;
D O I：
10.3324/haematol.2008.001271
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：7 / 10
页数：4
相关论文
共 50 条
  • [21] JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis?
    Stolyar, M. A.
    Klimova, O. A.
    Gorbenko, A. S.
    Brenner, E. V.
    Titov, S. E.
    Ivanov, M. K.
    Olkhovskiy, I. A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) : E8 - E10
  • [22] The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera
    Ancochea, Agueda
    Alvarez-Larran, Alberto
    Morales-Indiano, Cristian
    Garcia-Pallarols, Francesc
    Martinez-Aviles, Luz
    Angona, Anna
    Senin, Alicia
    Bellosillo, Beatriz
    Besses, Carles
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (03) : 411 - 417
  • [23] Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
    Drofenik, Ajda
    Blinc, Ales
    Mijovski, Mojca Bozic
    Pajic, Tadej
    Vrtovec, Matjaz
    Sever, Matjaz
    RADIOLOGY AND ONCOLOGY, 2024, 58 (04) : 565 - 572
  • [24] Neutrophilia and the JAK2 V617F Mutation
    Langabeer, Stephen E.
    Haslam, Karl
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 437 - 438
  • [25] Splenomegaly and the JAK2 V617F mutation
    Langabeer, Stephen E.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 37 : E45 - E46
  • [26] Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Pardanani, Animesh D.
    Burn, Timothy
    Vaddi, Kris
    Redman, John
    Bradley, Edward C.
    Levy, Richard
    Friedman, Steven
    Hollis, Gregory
    Tefferi, Ayalew
    BLOOD, 2008, 112 (11) : 968 - 968
  • [27] Correlation of JAK2 V617F Mutation Burden with Clinical and Hematologic Characteristics of Myeloproliferative Neoplasms
    Brown, A. F.
    Wang, Y.
    Abu-Ghusson, M. M.
    George, P. A.
    Vadlamudi, K.
    Furmaga, W. B.
    Fan, H.
    MODERN PATHOLOGY, 2013, 26 : 321A - 321A
  • [28] JAK2 (V617F) mutation burden, phenotype, and clinical course of chronic myeloproliferative disorders
    Passamonti, F.
    Rumi, E.
    Pietra, D.
    Della Porta, M. G.
    Boveri, E.
    Elena, C.
    Boggi, S.
    Arcaini, L.
    Pascutto, C.
    Lazzarino, M.
    Cazzola, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 243 - 243
  • [29] Correlation of JAK2 V617F Mutation Burden with Clinical and Hematologic Characteristics of Myeloproliferative Neoplasms
    Brown, A. F.
    Wang, Y.
    Abu-Ghusson, M. M.
    George, P. A.
    Vadlamudi, K.
    Furmaga, W. B.
    Fan, H.
    LABORATORY INVESTIGATION, 2013, 93 : 321A - 321A
  • [30] In the interest of the mass screening of the JAK2(V617F) mutant in the general public
    Ianotto, Jean-Christophe
    HEMATOLOGIE, 2013, 19 (01): : 11 - 11
12345